Literature DB >> 10648034

Anxiety and depression in patients with primary Sjögren's syndrome.

S T Valtýsdóttir1, B Gudbjörnsson, U Lindqvist, R Hällgren, J Hetta.   

Abstract

OBJECTIVE: To examine the degree of anxiety and depression and to assess well being and general symptoms in patients with primary Sjögren's syndrome (SS).
METHODS: A standardized questionnaire, the Hospital Anxiety and Depression Scale, was used to examine the degree of anxiety and depression in patients with primary SS (n = 62) and in age matched healthy female controls. The Gothenburg quality of life instrument (GQOL) was used to assess well being and general symptoms. Patients with rheumatoid arthritis (RA; n = 38) were used as patient controls.
RESULTS: The patients with primary SS had significantly higher scoring rate for "possible" clinical anxiety (48%) and for "possible" clinical depression (32%) compared with reference groups (p<0.05). The physical and mental well being of the patients with primary SS were significantly reduced compared with controls. Furthermore, patients with primary SS complained more commonly of low mood, irritability, headache, gastrointestinal symptoms, and impaired concentration and memory than the patients with RA.
CONCLUSION: The results indicate that patients with primary SS often have psychiatric symptoms and worse well being, which may affect their quality of life.

Entities:  

Mesh:

Year:  2000        PMID: 10648034

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  21 in total

Review 1.  CNS involvement in primary Sjögren's syndrome: prevalence, clinical aspects, diagnostic assessment and therapeutic approach.

Authors:  M Govoni; M Padovan; N Rizzo; F Trotta
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 2.  New Treatment Guidelines for Sjögren's Disease.

Authors:  Frederick B Vivino; Steven E Carsons; Gary Foulks; Troy E Daniels; Ann Parke; Michael T Brennan; S Lance Forstot; R Hal Scofield; Katherine M Hammitt
Journal:  Rheum Dis Clin North Am       Date:  2016-08       Impact factor: 2.670

Review 3.  Unraveling the pathophysiology of Sjogren syndrome-associated dry eye disease.

Authors:  Cuong Q Nguyen; Ammon B Peck
Journal:  Ocul Surf       Date:  2009-01       Impact factor: 5.033

4.  Characterization of cognitive dysfunction in Sjögren's syndrome patients.

Authors:  Lynn C Epstein; Gina Masse; Jerold S Harmatz; Tammy M Scott; Athena S Papas; David J Greenblatt
Journal:  Clin Rheumatol       Date:  2013-12-15       Impact factor: 2.980

5.  Transcriptome analysis of the interferon-signature defining the autoimmune process of Sjögren's syndrome.

Authors:  A B Peck; C Q Nguyen
Journal:  Scand J Immunol       Date:  2012-09       Impact factor: 3.487

6.  Evaluation of Swallowing Functions in Patients with Sjögren's Syndrome.

Authors:  Sibel Eyigör; Baha Sezgin; Gonca Karabulut; Kerem Öztürk; Sercan Göde; Tayfun Kirazlı
Journal:  Dysphagia       Date:  2016-11-12       Impact factor: 3.438

7.  Mental wellbeing and quality of sexual life in women with primary Sjögren's syndrome are related to circulating dehydroepiandrosterone sulphate.

Authors:  S Th Valtysdottir; L Wide; R Hallgren
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

Review 8.  Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A).

Authors:  Laura J Julian
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

Review 9.  Depression and anxiety in dry eye disease: a systematic review and meta-analysis.

Authors:  K H Wan; L J Chen; A L Young
Journal:  Eye (Lond)       Date:  2016-08-12       Impact factor: 3.775

10.  Primary Sjögren's Syndrome: health experiences and predictors of health quality among patients in the United States.

Authors:  Barbara Segal; Simon J Bowman; Philip C Fox; Frederick B Vivino; Nandita Murukutla; Jeff Brodscholl; Sarika Ogale; Lachy McLean
Journal:  Health Qual Life Outcomes       Date:  2009-05-27       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.